This book provides the framework for a singular reference in the field of pulmonary hypertension. Pulmonary vascular disease is a complex and heterogeneous condition characterized by remodeling of distal pulmonary arterioles that increases pulmonary vascular resistance to affect cardiopulmonary hemodynamic and right ventricular function adversely, resulting in a clinical syndrome of diminished exercise tolerance, shortness of breath, and heart failure-associated morbidity and mortality. Owing to the availability of novel pulmonary circulation-selective pharmacotherapies over the previous decade, the number of pulmonary hypertension patients eligible for treatment has increased substantially. Despite this progress, under-awareness persists within the practicing pulmonary, cardiovascular, and general internal medicine communities. This is due, in part, to the complex array of molecular mechanisms implicated in the pathobiology of PH, as well as cutting-edge discoveries from translationalscientific works that provide a new framework by which to understand pulmonary vascular-right ventricular coupling. Taken together, a key educational opportunity is exposed to bridge this knowledge gap through the synthesis of a contemporary text that emphasizes basic science, translational and clinical principles, and treatment strategies for understanding pulmonary hypertension. “This is a comprehensive book on the important clinical topic of pulmonary hypertension, and one of the most up to date on this emerging field of study. … The intended audience is specialists in the field of cardiology and pulmonology. … This book is useful for both clinicians and those interested in basic science and translational research.” (Shubhum Misra, Doody's Book Reviews, February, 2016) This definitive textbook details the rapid advances in epidemiology, pathobiology and therapeutics in the field of pulmonary hypertension. Despite recent progress, under-awareness persists within the practicing pulmonary, cardiovascular, and general internal medicine communities. This is due, in part, to the complex array of molecular mechanisms implicated in the pathobiology of PH, as well as cutting-edge discoveries from translational scientific works that provide a new framework by which to understand pulmonary vascular-right ventricular coupling. This book bridges this knowledge gap through the synthesis of a contemporary text that emphasizes basic science, translational and clinical principles, and treatment strategies for understanding pulmonary hypertension. Pulmonary Hypertension: Basic Science to Clinical Medicine is the essential reference for any physician or scientist with an interest in pulmonary hypertension. The Editors and their hugely knowledgeable listof contributors have provided a contemporary, comprehensive overview of the field in all of its complexity that will be vital for all levels of clinician, researcher and trainee in respiratory medicine, cardiology, critical care and all disciplines involved in the management of patients with pulmonary hypertension. Bradley A. Maron, M.D. is an Assistant Professor of Medicine at Harvard Medical School (HMS), Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, and Co-director of the Pulmonary Vascular Disease Center at the Boston VA Healthcare System. His research focuses on the basic mechanisms underpinning adverse pulmonary vascular remodeling. Dr. Maron’s research is funded by the NIH, among other prestigious foundations. He is also an Eleanor and Miles Shore Scholar in Medicine and HMS Excellence in Teaching award recipient. Roham T. Zamanian, M.D. is an Assistant Professor of Medicine and Director of the Adult Pulmonary Hypertension Program at Stanford University School of Medicine. Dr. Zamanian completed medical school and Internal Medicine training at the University of California, Irvine Medical Center and fellowship in Pulmonary and Critical Care Medicine at Stanford University. Dr. Zamanian was also an eBay Pulmonary Vascular Disease super-fellow at the Vera Moulton Wall Center (VMWC) for Pulmonary Vascular Diseases at Stanford University. Besides an active clinical career, Dr. Zamanian is a translational scientist focusing on the discovery of novel biochemical and clinical risk factors for pulmonary vascular disease. Dr. Zamanian’s research is funded by the NIH and VMWC. Aaron Waxman, M.D., Ph.D., is the Executive Director of the Center for Pulmonary Heart Diseases at the Brigham and Women’s Hospital (BWH) Heart and Vascular and Lung Centers. Dr. Waxman directs the Pulmonary Vascular Disease Program at BWH. His interests focus on integrating clinical and basic investigations to understand further pulmonary vascular disease and right heart failure. Dr. Waxman directs a robust NIH-funded clinical and basic research program, posts leadership roles in several international organizations, and collaborates actively with clinical experts and inv